Intelligent Bio Solutions Inc. to Showcase Fingerprint Sweat PK Study at ADLM 2025 Clinical Lab Expo

Intelligent Bio Solutions Inc. (NASDAQ: INBS), a leader in non-invasive medical testing technologies, is set to present its groundbreaking pharmacokinetic (PK) study at the ADLM 2025 Clinical Lab Expo in Chicago. The study underscores the efficacy of the company's Intelligent Fingerprinting Drug Screening System, demonstrating that fingerprint sweat can accurately reflect codeine levels comparable to those found in blood and saliva. This advancement supports the system's role as a viable, non-invasive alternative for drug screening in various settings.

Daniel Brown, Head of Clinical Affairs at INBS, will present the findings, which could significantly impact workplace, clinical, and justice system drug testing protocols. The Intelligent Fingerprinting Drug Screening System offers a rapid, hygienic, and cost-effective solution for detecting recent drug use, with results available in under ten minutes. This technology is particularly relevant for safety-critical industries, providing a dignified and efficient testing method.

With a presence in over 450 accounts across 24 countries, INBS continues to innovate in the field of portable drug testing. The upcoming presentation at the ADLM 2025 Clinical Lab Expo marks a pivotal moment for the company and the broader medical technology industry, showcasing the potential of fingerprint sweat analysis beyond traditional drug screening methods.